Rheumatoid Arthritis Treatment Guidelines

Initial Treatment Approach

The American College of Rheumatology recommends that therapy with disease-modifying antirheumatic drugs (DMARDs) should be started immediately upon diagnosis of rheumatoid arthritis to prevent joint damage and disability, with methotrexate as the anchor drug, starting with 15mg weekly and titrating up to 20-25mg weekly or maximum tolerated dose, and short-term low-dose glucocorticoids should be added to initial therapy to provide rapid symptomatic relief while waiting for DMARDs to take effect 1, 2
For patients with contraindications to methotrexate, leflunomide or sulfasalazine should be considered as alternative first-line agents 2

The European League Against Rheumatism recommends that treatment should aim for clinical remission (or at minimum low disease activity) as the primary target, with disease activity monitored frequently (every 1-3 months) during active disease 1, 2, 3
If no improvement is seen within 3 months or the target is not reached by 6 months, therapy should be adjusted 2, 3

For patients with poor prognostic factors, such as presence of autoantibodies, high disease activity, early erosions, or failure of two conventional synthetic DMARDs, a biological DMARD or JAK inhibitor should be added to methotrexate 1, 2
Options for biological DMARDs include TNF inhibitors, IL-6 inhibitors, T-cell co-stimulation modulators, B-cell depleting therapy, or JAK inhibitors 1, 2, 4

If the first biological DMARD or JAK inhibitor fails, switch to another biological DMARD or JAK inhibitor from either the same or a different class 1, 2
For patients who fail TNF inhibitor therapy, consider switching to a different mechanism of action, such as abatacept, tocilizumab, rituximab, or a JAK inhibitor 2, 4

For isolated joint flares, consider intra-articular glucocorticoid injections, and for systemic flares, short-term oral glucocorticoids may be used 5, 6

In patients who achieve sustained remission, cautious tapering of DMARDs can be considered, typically tapering biologics first, then reducing conventional DMARDs 1, 2, 3, 5
Complete drug-free remission is achievable in only 15-25% of patients; most will require some ongoing DMARD therapy 3, 5